CLDN18 and gastric cancer: The present study demonstrated that CLDN18 positivity in G/EGJ with PM was 31.1% at 75% cut-off in primary tumors, in agreement with a recent study [33] on gastric cancer with PM which reported a positivity rate of 28.6%.